GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

Published Apr 05 2021 at 8:19 AM GMT
Key
Points
  • New York, April 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker com announces the release of the report "GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028" - https://www reportlinker com/p06010867/'utm_source=GNW MARKET INSIGHTSNon-alcoholic steatohepatitis (NASH), a highly destructive form of non-alcoholic fatty liver disease (NAFLD), often develops into more severe disorders, like hepatocellular carcinoma and cirrhosis.
  • As a result, NASH is projected to surpass the hepatitis C virus infection and become the leading cause of liver transplantation, worldwide, over the upcoming decade.
  • As these diseases progress, the liver experiences fibrosis and scarring, ultimately leading to cirrhosis.
  • Liver fibrosis is likely to result in permanent organ damage, progress to hepatocellular carcinoma, and liver failure.
  • Obesity is a well-recognized epidemic, globally.




Stats

  • Published Apr 5, 2021 8:19 AM GMT